Share on StockTwits

ResMed (NYSE:RMD) Insider David Pendarvis unloaded 5,000 shares of ResMed stock on the open market in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.76, for a total transaction of $248,800.00. Following the sale, the insider now directly owns 69,207 shares of the company’s stock, valued at approximately $3,443,740. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on RMD shares. Analysts at Northland Securities downgraded shares of ResMed from a “market perform” rating to an “underperform” rating in a research note on Tuesday, May 27th. They now have a $40.00 price target on the stock. Separately, analysts at Deutsche Bank upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Thursday, April 24th. They now have a $52.00 price target on the stock. Finally, analysts at Morgan Stanley reiterated an “equal weight” rating on shares of ResMed in a research note on Thursday, April 24th. They now have a $46.08 price target on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $45.90.

ResMed (NYSE:RMD) traded up 2.17% during mid-day trading on Thursday, hitting $51.29. The stock had a trading volume of 529,839 shares. ResMed has a 52-week low of $41.52 and a 52-week high of $57.34. The stock’s 50-day moving average is $49.67 and its 200-day moving average is $46.79. The company has a market cap of $7.198 billion and a P/E ratio of 22.03.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Wednesday, April 23rd. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by $0.01. The company had revenue of $397.80 million for the quarter, compared to the consensus estimate of $401.00 million. During the same quarter in the previous year, the company posted $0.58 earnings per share. The company’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, analysts predict that ResMed will post $2.49 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Tuesday, June 17th. Stockholders of record on Tuesday, May 20th will be paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.95%. The ex-dividend date is Friday, May 16th.

ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.